Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.10 and traded as high as $6.25. Enzon Pharmaceuticals shares last traded at $6.1916, with a volume of 1,584 shares traded.
Enzon Pharmaceuticals Stock Performance
The firm has a market capitalization of $459.51 million, a P/E ratio of -88.44 and a beta of 0.20. The stock has a 50-day moving average of $0.19 and a 200 day moving average of $0.10.
Enzon Pharmaceuticals (OTCMKTS:ENZN - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.02) EPS for the quarter.
Enzon Pharmaceuticals Company Profile
(
Get Free Report)
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company's flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon's commitment to oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enzon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzon Pharmaceuticals wasn't on the list.
While Enzon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
